Literature DB >> 20832153

Dense deposit disease associated with monoclonal gammopathy of undetermined significance.

Sanjeev Sethi1, William R Sukov, Yuzhou Zhang, Fernando C Fervenza, Donna J Lager, Dylan V Miller, Lynn D Cornell, Srivilliputtur G Santhana Krishnan, Richard J H Smith.   

Abstract

Dense deposit disease (DDD) is a rare glomerular disease that typically affects children, young adults, and much less commonly, older patients. The pathophysiologic process underlying DDD is uncontrolled activation of the alternative pathway (AP) of complement cascade, most frequently secondary to an autoantibody to C3 convertase called C3 nephritic factor, although mutations in factor H and autoantibodies to this protein can impair its function and also cause DDD. Since 1995, we have diagnosed DDD in 14 patients aged 49 years or older; 10 of these patients (71.4%) carry a concomitant diagnosis of monoclonal gammopathy of undetermined significance (MGUS). In 1 of these 10 patients, the index case described here, we evaluated the AP and showed low serum AP protein levels consistent with complement activity, heterozygosity for the H402 allele of factor H, and low levels of factor H autoantibodies, which can affect the ability of factor H to regulate AP activity. In aggregate, these findings suggest that in some adults with MGUS, DDD may develop as a result of autoantibodies to factor H (or other complement proteins) that on a permissive genetic background (the H402 allele of factor H) lead to dysregulation of the AP with subsequent glomerular damage. Thus, DDD in some older patients may be a distinct clinicopathologic entity that represents an uncommon complication of MGUS.
Copyright © 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832153      PMCID: PMC3970198          DOI: 10.1053/j.ajkd.2010.06.021

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  18 in total

Review 1.  Complement factor H: physiology and pathophysiology.

Authors:  P F Zipfel
Journal:  Semin Thromb Hemost       Date:  2001-06       Impact factor: 4.180

2.  Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).

Authors:  M A Abrera-Abeleda; C Nishimura; J L H Smith; S Sethi; J L McRae; B F Murphy; G Silvestri; C Skerka; M Józsi; P F Zipfel; G S Hageman; R J H Smith
Journal:  J Med Genet       Date:  2005-11-18       Impact factor: 6.318

Review 3.  Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.

Authors:  Gerald B Appel; H Terence Cook; Gregory Hageman; J Charles Jennette; Michael Kashgarian; Michael Kirschfink; John D Lambris; Lynne Lanning; Hans U Lutz; Seppo Meri; Noel R Rose; David J Salant; Sanjeev Sethi; Richard J H Smith; William Smoyer; Hope F Tully; Sean P Tully; Patrick Walker; Michael Welsh; Reinhard Würzner; Peter F Zipfel
Journal:  J Am Soc Nephrol       Date:  2005-03-30       Impact factor: 10.121

4.  Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice.

Authors:  M C Pickering; J Warren; K L Rose; F Carlucci; Y Wang; M J Walport; H T Cook; M Botto
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

5.  Dense deposit disease in association with monoclonal gammopathy of unknown significance.

Authors:  F Sepandj; A Trillo
Journal:  Nephrol Dial Transplant       Date:  1996-11       Impact factor: 5.992

6.  Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H.

Authors:  T S Jokiranta; A Solomon; M K Pangburn; P F Zipfel; S Meri
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

7.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

Authors:  Sanjeev Sethi; Jeffrey D Gamez; Julie A Vrana; Jason D Theis; H Robert Bergen; Peter F Zipfel; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

8.  Crescentic glomerulonephritis and dense deposit disease in a woman with breast carcinoma on immunosuppressive chemotherapy.

Authors:  Sanjeev Sethi; Mandeep Sahani; Liem Som Oei; Radha Rao
Journal:  Am J Kidney Dis       Date:  2004-09       Impact factor: 8.860

9.  Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency.

Authors:  K Høgåsen; J H Jansen; T E Mollnes; J Hovdenes; M Harboe
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

10.  Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis.

Authors:  S Meri; V Koistinen; A Miettinen; T Törnroth; I J Seppälä
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

View more
  51 in total

1.  Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.

Authors:  Shuju Feng; Stephen J Eyler; Yuzhou Zhang; Tara Maga; Carla M Nester; Michael H Kroll; Richard J Smith; Vahid Afshar-Kharghan
Journal:  Blood       Date:  2013-07-11       Impact factor: 22.113

Review 2.  The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Authors:  Sanjeev Sethi; S Vincent Rajkumar; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2018-04-27       Impact factor: 10.121

3.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

Review 4.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

5.  Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy?

Authors:  Mariana Ciocchini; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2018-05-28       Impact factor: 2.370

Review 6.  Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity.

Authors:  Mariana Ciocchini; Jorge Arbelbide; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2017-04-19       Impact factor: 2.370

7.  C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; Sanjeev Sethi
Journal:  Kidney Int       Date:  2018-05-03       Impact factor: 10.612

8.  C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; An S De Vriese; Sanjeev Sethi
Journal:  Mayo Clin Proc       Date:  2018-08       Impact factor: 7.616

Review 9.  Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury?

Authors:  Mona Doshi; Amit Lahoti; Farhad R Danesh; Vecihi Batuman; Paul W Sanders
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

Review 10.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.